Streetbeat News

Price Targets

CI

Analysts have provided varied ratings for Cigna Group (NYSE:CI) over the last quarter, with recent updates showing a mix of 'Maintain', 'Raise', and 'Outperform' recommendations. The average 12-month price target for CI has increased to $340.43, up from $324.00, with a high estimate of $372.00 and a low of $327.00. Cigna's financials indicate strong market presence, revenue growth, and efficient cost management, with a market cap above industry benchmarks, a positive revenue trend, and a net margin of 2.87%. The company's ROE and ROA also surpass industry standards, and it has a conservative debt-to-equity ratio of 0.68.

Portfolio Pulse from Benzinga Insights

January 04, 2024 | 4:00 pm

ALKT

Alkami Technology (NASDAQ:ALKT) has been analyzed by 5 analysts, showing a shift towards a more positive outlook with an average 12-month price target of $24.00, up from $21.25. Analysts from Barclays, Stephens & Co., JMP Securities, JP Morgan, and Needham have adjusted their ratings and price targets, reflecting changes in market conditions and company performance. Alkami's financials indicate strong revenue growth but below-average profitability and efficiency metrics. The company's low debt-to-equity ratio suggests a healthy balance of financing.

Portfolio Pulse from Benzinga Insights

January 04, 2024 | 4:00 pm

WDAY

Workday (NASDAQ:WDAY) has received diverse analyst ratings over the last three months, with a shift towards more bullish sentiment in the last 30 days. The average 12-month price target for WDAY is now $282.72, up from the previous $255.94. Analysts from firms like Keybanc, Piper Sandler, and Morgan Stanley have raised their price targets, reflecting optimism about the company's performance. Workday's financial health indicators show a strong market presence with a market cap above industry average, a positive revenue trend with a growth rate of 16.67%, but challenges in profitability and asset utilization with lower than industry average net margin, ROE, and ROA.

Portfolio Pulse from Benzinga Insights

January 04, 2024 | 4:00 pm

EMR

Six analysts have recently updated their ratings on Emerson Electric (NYSE:EMR), with a mix of bullish and bearish sentiments. The average 12-month price target is $108.83, with a high of $120 and a low of $95. Analysts from firms including Mizuho, Wells Fargo, UBS, Stephens & Co., RBC Capital, and Citigroup have adjusted their price targets and ratings, reflecting their latest views on the company's performance. Emerson Electric operates in automation equipment and services, with a strong market position indicated by its market capitalization, revenue growth, net margin, ROE, ROA, and a healthy debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 04, 2024 | 4:00 pm

LPX

Truist Securities analyst Michael Roxland has reaffirmed a Buy rating on Louisiana-Pacific (NYSE:LPX) and increased the price target from $75 to $82, indicating a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 3:58 pm

LSTA

HC Wainwright & Co. analyst Joseph Pantginis has reiterated a Buy rating on Lisata Therapeutics (NASDAQ:LSTA) and maintained a price target of $15. This endorsement from a reputable analyst could influence investor sentiment and potentially impact the stock's short-term performance.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 3:54 pm

PKG

Truist Securities analyst Michael Roxland has reaffirmed a Buy rating on Packaging Corp of America (NYSE:PKG) and increased the price target from $170 to $187.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 3:54 pm

PCH

Truist Securities analyst Michael Roxland has maintained a Hold rating on PotlatchDeltic (NASDAQ:PCH) and increased the price target from $50 to $51.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 3:51 pm

RYN

Truist Securities analyst Michael Roxland has maintained a Hold rating on Rayonier (NYSE:RYN) and increased the price target from $33 to $34.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 3:47 pm

ATAI

HC Wainwright & Co. analyst Patrick Trucchio has reiterated a Buy rating on ATAI Life Sciences (NASDAQ:ATAI) and maintained a $20 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

January 04, 2024 | 3:46 pm